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Objectives. To understand the perceived benefits and drawbacks of a mild cognitive
impairment (MCI) diagnosis from the perspective of those living with the label.
Methods. Participants were included if they had recently (within 6 months) received a
MCI diagnosis. We also recruited close family members to gain their perspectives. Each
was interviewed separately with a semi-structured topic guide covering three areas: (1)
experience of cognitive impairments and changes in the individual; (2) impact of cognitive
impairment(s) on daily activities and social relationships; and (3) experience of the
diagnosis process and living with the label. Transcribed interviewswere stored inNvivo.
Grounded theory procedures of memo writing, open coding, constant comparison, and
focused coding were used to derive conceptual themes.
Results. Eighteen dyads were interviewed. The overarching themes surrounding diagnosis
benefits and drawbacks were as follows: (1) emotional impact of the diagnosis; (2) practical
benefits and limitations of the diagnosis, in termsof (a) understanding one’s symptoms and (b)
access to clinical support. Although participants were glad to have clinical support in place,
they expressed frustration at the lack of clarity, and the lack of available treatments for MCI.
Consequently, living with MCI can be characterized as an ambivalent experience.
Conclusion. As a clinical label, MCI appears to have little explanatory power for people
living with cognitive difficulties. Work is needed to clarify how clinicians and patients
communicate aboutMCI, and howpeople can be helped to livewell with the label. Despite
an emerging body of prognostic studies, people with MCI are likely to continue living with
significant uncertainty.
Statement of contribution
What is already known on this subject?
Mild cognitive impairment is a state of cognitive decline between normal cognitive ageing and dementia.
This clinical category hasbeenan important domainof academicdebateover recent years. Fromaclinical
perspective, diagnosingMCI is a helpful way to enable communication between health professionals, and
a diagnosis can be important for patients in need of support and education. However, diagnosis can be
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fraught with difficulties, while patients have reported significant uncertainty about the label. This study
aimed to examine the perceived benefits and drawbacks of receiving a MCI diagnosis.
What does this study add?
 The emotional impact of a MCI diagnosis is complex and raised conflicting and fluctuating emotions
in our participants’ accounts – most notably worry and relief.
 Participants were glad to have clinical support available to call on; however, they were frustrated at
the lack of ‘treatments’ available forMCI andwere often anxious to slow any cognitive decline down
 Health psychologists will have an important role to play in understanding and improving clinical
communication about MCI
Mild cognitive impairment (MCI) describes a level of cognitive impairment between that
seen in ‘normal’ ageing and dementia. MCI was identified in the clinical literature as early
as the mid-1990s (e.g., Petersen, 1995), but interest in the syndrome increased following
the publication of formal MCI criteria by Ronald Petersen’s Mayo Clinic team (Petersen
et al., 1999). These criteria consisted of (1) memory complaint, preferably corroborated
by an informant; (2) objective memory impairment; (3) preserved general cognition; (4)
intact activities of daily living; and (5) no dementia. Petersen et al. (1999) followed a
cohort of people whomet these criteria and found a greater rate of cognitive decline than
that seen in healthy older adults over time, but not as great as that observed in a
comparison group of people with mild Alzheimer’s disease (AD). In addition, the MCI
group showed impairment only in memory, while those with mild AD had accompanying
deficits in other cognitive domains. Consequently, it was argued that MCI was a distinct
clinical syndrome worthy of further study.
Since then, MCI has been a subject of debate and investigation with respect to
prevalence (Ward, Arrighi, Michaels, & Cedarbaum, 2012), existence and prognostic
value of different subtypes (Mitchell & Shiri-Feshki, 2009; Petersen, 2004), medical
management (Petersen, 2003), and the clinical utility and ethical implications of the label
(Beard & Neary, 2013; Sabat, 2006; Werner & Korczyn, 2008; Whitehouse & Moody,
2006). Such debates are reflected in diagnostic manuals, which conceptualize MCI
differently: While the ICD 10 lists MCI as a discrete category, focusing on clinical
presentation (World Health Organization, 2004), the Diagnostic and Statistical Manual
(DSM V) makes no reference to MCI (American Psychiatric Association, 2013). Instead
mild neurocognitive disorder is listed, and clinicians are required to state the disease
process underlying the cognitive impairment. Recently, attention has focused on
consolidating MCI as a clinical entity (Albert et al., 2011; Petersen, 2016), and seeking to
prevent transition to dementia (e.g., Allan, Behrman, Ebmeier, & Valkanova, 2016).
However, while research is beginning to show promising predictive value of some
biomarkers for defining subtypes and estimating the probability of progression to
dementia (Petersen et al., 2009), these are often unavailable in routine clinical practice.
Additionally, not everyone with MCI will progress to dementia or AD, and some will live
with the syndrome for the rest of their lives, or even revert to normal cognitive function
(Mitchell & Shiri-Feshki, 2009; Sachdev et al., 2013). Consequently, a number of social
scientists have come to view recent nosological changes associatedwithMCI as examples
of what the historian of psychiatry, Nikolas Rose (2006), has called ‘disorders without
borders’ – that is, progressive erosion of what counts as ‘normal’ (Beard, 2016; Beard &
Neary, 2013; Moreira et al., 2008). Others have cautioned against the ‘Alzheimerization’
of MCI, emphasizing the importance of understanding the psychosocial and occupational
needs of each individual (Fang et al., 2017; Whitehouse & Moody, 2006).
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Amid these debates, it is important to keep in mind the complex, sometimes
paradoxical implications that clinical labels can have for those living with them. Although
referring to someone as ‘cognitively impaired’ can leave them open to stigma (Beard &
Neary, 2013; Saunders, de Medeiros, & Bartell, 2011), clinical labels can help make sense
of symptoms (Verhaeghe, 2008) and enable access to various forms of clinical and
occupational support. Recently emerging research has highlighted the experience of
living with MCI (Gomersall et al., 2015), but little is known about the perceived benefits
and drawbacks of an MCI diagnosis from the perspective of those living with the label.
This article examines the experience of receiving anMCI diagnosis in terms of the benefits
and drawbacks this diagnosis confers on individuals and their families.
Methods
Ethics
This study was granted ethical clearance by the South Yorkshire NHS Research
Ethics Committee in the UK. Signed informed consent was taken from people with
MCI and their family members separately, and participants were debriefed at the end
of the interviews. During the fieldwork, we did encounter an unanticipated ethical
issue. Some participants did not recall hearing the term MCI, and some sought
advice and even treatment from the interviewers. In these cases, we explained what
we understood about MCI from the research literature while emphasizing we were
not qualified to offer medical advice or treatment, and asking the participants
whether they wished us to re-refer them to the collaborating memory clinic. In
addition, we ensured continued informed consent.
Participants
Participants were included if they were recently (within 6 months) diagnosed with MCI,
fluent English speakers, able to provide informed consent, with no other known
neurocognitive conditions. CB, a clinician in thememory clinic service, identified everyone
who had been coded as havingMCI within the last 6 months on the clinic database. To our
knowledge, no participants had subsequent contact with the memory clinic from the date
of the recorded diagnosis. We also recruited a family member of each participant to gain
their perspective. Although purposive sampling is often recommended for qualitative
studies (Devers & Frankel, 2000), opportunity sampling was used due to the small pool of
potential participants with a recent MCI diagnosis from the collaborating Memory Service.
Figure 1 illustrates the UKNational Institute for Health and Care Excellence dementia
diagnosis pathway,which is also followed forMCI. First, an evaluation is conductedwith a
dementia screening instrument such as the Addenbrooke’s Cognitive Assessment –
Revised (Mioshi, Dawson, Mitchell, Arnold, & Hodges, 2006) and blood tests are taken to
rule out possible non-neurological causes of cognitive decline. If this evaluation is
inconclusive, further neuropsychological tests are available – including CT scans and
more detailed assessments of specific cognitive domains. When a person receives an MCI
diagnosis, they have a post-diagnosis needs assessment, including support from
occupational therapy and lifestyle change suggestions. However, no specific treatments
are currently recommended forMCI in theUnitedKingdom. Rather, people showing signs
of MCI are regularly monitored, with a follow-up in 6–12 months. This approach to
clinical management differs between countries – for example, in the US clinicians may
treat MCI with Cholinesterase inhibitors.
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Data collection and management
Interviews were conducted using semi-structured topic guides (Appendix 1). People
with MCI and their family members were each asked to cover three key areas: (1)
experience of cognitive impairments and changes in the person; (2) impact of cognitive
impairment(s) on daily activities and social relationships; and (3) experience of the
diagnosis process and livingwith the label. Although clinicalMCI criteria specify that daily
activities should remain intact, we wished to examine people’s experience, as recent
qualitative research has found that more complex activitiesmay be affected (e.g., Binegar,
Step 1
Person with suspected dementia
Step 2
Investigation of possible 
dementia
Step 3
Specialist assessment services
Step 4
Diagnosis and assessment
Step 5
Diagnosis of subtype
Step 6
Needs assessment
Step 7
Intervention
Figure 1. Diagnostic process for dementia and mild cognitive impairment.
4 Tim Gomersall et al.
Hynan, Lacritz, Weiner, & Cullum, 2009; Kim et al., 2009; Nygard, Pantzar, Uppgard, &
Kottorp, 2012). In follow-up probes, open-ended and action-oriented questions were
used to encourage storytelling. The interviewers (TG and SKS) alternated between
interviewing people diagnosed with MCI and their family members, to ensure a balance
between their interviewing styles in each group. Interviews were transcribed verbatim,
including key non-linguistic communicationmarkers (e.g., laughter, crying, long pauses),
and anonymized transcriptswere entered inNvivo for storage and analysis. In addition to
the qualitative data, we used the Montreal Cognitive Assessment (MoCA, Nasreddine
et al., 2005) to gain an indication of the current level of cognitive performance of our
participants with MCI.
Analysis
A grounded theory analysis (Charmaz, 2014) was undertaken. First, TG and CB assigned
open codes, line-by-line, to each interview transcript. At this point, we remained
grounded in the data using participants’ words as coding labels where possible, and by
freely applying new codes to the interviews as new ideas emerged. An initial phase of
constant comparisonwas conducted independently by two coders, inwhichwe sought to
identify recurring patterns in the data, and to reduce the codes to increased levels of
abstraction. Memos were written and linked to specific parts of interview texts to record
our developing ideas about the data. Then, we compared our respective coding labels,
asking ourselves what was going on in the data and which labels best captured the
phenomenon being described. These labels became our themes, which were further
compared and reduced.While a variety of themes were developed, this article focuses on
one particularly important phenomenon: the perceived benefits and drawbacks of a MCI
diagnosis. This overarching issue of ‘benefits and drawbacks’ showed three thematic
dimensions: the affective impact of the diagnosis; understanding one’s problems; and the
impact of clinical support.
Trustworthiness and reflexivity
A sample of four randomly selected interviewswas independently double-coded using the
final coding framework, andNvivowas used to calculate the kappa statistic. Kappa gives
an estimate of inter-rater agreement between 0 (chance agreement) and 1 (perfect
agreement). Values between .21 and .4 were taken to indicate fair agreement, .41 to .6
indicated moderate agreement, and .61 to .8 indicated substantial agreement (Viera &
Garrett, 2005). We also discussed any notable differences between the two coders, and
whether we needed to rethink any of our conceptual themes.
Grounded theory has roots in symbolic interactionism (Corbin & Strauss, 2014)which
posits that meaning is co-constructed between researchers and participants. Therefore,
we sought to recognize how our own characteristics and assumptions impacted the data
collection and interpretation (Finlay&Gough, 2003). In this case, the research design, and
the way we approached the data, was largely driven by our interest as clinicians and
academic psychologists in the impact of MCI on the person’s sense of self, and their
experiences of clinical services and labelling. Our epistemological standpoint was critical
realism (Bhaskhar, 2014) – we assumed participants’ words ‘gave voice’ to a real
experience, but their accounts (and our interpretations) were coloured by surrounding
cultural, social, and linguistic contexts – including the availability of the MCI label itself.
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Findings
Participants
Of 42 eligible people with MCI identified on the clinic database, nine women and
nine men agreed to participate. Their ages ranged from 60 to 93 years
(mean = 77.4  8.6). MoCA scores ranged from 14 to 30 (mean 22.7  3.9,
Table 1), suggesting some participants scored outside the bounds of what would
typically be expected in MCI (i.e., 18–26). Participants were homogeneous in terms
of ethnicity, with all identifying as white British. There was some spread in terms of
socioeconomic status, with most participants completing high school education to
age 16, three having obtained a first degree, and one having a higher degree. The
English Indices of Multiple Deprivation (IMD) were used to give some indication of
the relative deprivation of the areas in which our participants lived. The IMD
combine data on seven domains to provide an overall measure of deprivation in
small areas in England: income; employment; education, training, and skills; health
and disability; crime; barriers to housing services; and living environment. As can be
seen in Table 1, our participants tended to cluster in the top and bottom deciles of
deprivation, reflecting the pattern seen in the city we conducted our fieldwork. The
relatives of people with MCI included four daughters, six husbands, six wives, and
two sons. Relatives’ ages ranged from 42 to 87 years old (mean = 66.4  16 years,
Table 2). The kappa value for inter-rater agreement on the coding was 0.475,
indicating moderate agreement.
Table 1. Participant characteristics
N Mean (SD)
Gender
Female 9
Male 9
Age (Years)
60–70 3 77.4 (8.6)
71–80 9
81+ 6
MoCA 22.7 (3.9)
IMD (by decile)
1–2 7
3–4 0
5–6 1
7–8 6
9–10 4
Education
High School 13
College to 18 1
1st degree 3
2nd degree 1
IMD, Indices of Multiple Deprivation (2015 data). Lower IMD scores represent more deprived areas;
MoCA, Montreal Cognitive Assessment score; SD, standard deviation.
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Benefits and drawbacks of a MCI diagnosis
Between relief and worry: The affective impact of a MCI diagnosis
Participants expressed a wide range of emotional responses to diagnosis, including
sadness, anger, loss, rationalization, and humour. However, the two most commonly
cited responses to the diagnosis were worry and relief. Many participants expected
to receive a diagnosis of dementia or AD and were glad to hear this was not the
case. In one narrative, a participant had previously been told she had AD based on
the result of her CT scan. She described being ‘devastated, absolutely wiped out’ on
hearing this, and when she was later given the MCI diagnosis, she was ‘over the
moon’:
Extract 1.
Alison: She says ‘yeah you haven’t got it [AD]’ she says ‘it could be a lead up to it but not
everybodyhas a leadup to it’, she says ‘you justdowhat they say. Followwhat they say’ she says
‘andI’mbookingyouintoseewhoever it is this ladyertohelpyou’ Isays ‘but theysaidtheywere
gonnayouweregonnagethedidhesaidwe’dgiveyousometablets. . . tohelpyou’ andshesays
‘we’venothadnonote for any tablets’ she saider. . . ‘go to see this here ladyerfirst and seehow
you get on with that’ and y’know, blah-blah-blah. So. . . I’m doing what they say.
Int: Of course, of course.
Alison: Yeah.
Int: So. . . what did you make of that information you first got? You’ve said a bit about. . .
Alison: I were over the flippin moon! (laughs) (woman with MCI, 69 years old)
This sense of relief was seen throughout the interviews, suggesting widespread
fear about the possibility of developing dementia or specifically AD. Unusually, in
one case, a participant had been worried about brain cancer. In Extract 2, she hints
that she had a similar (mis)diagnosis of AD, but her reaction is very different to the
previous participant. The diagnosis is described, colloquially, as ‘a touch of
Alzheimer’s’, and her main response seems to be curiosity (‘ooh, what’s that?’)
and concerns about medication (‘have I got to take tablets?’). Her account highlights
how prior knowledge of different conditions can impact how a person anticipates,
and responds to, clinical terminology:
Table 2. Participant’s relative’s characteristics
Relatives N Average (SD)
Gender
Female 10
Male 8
Relationship
Daughter 4
Husband 6
Son 2
Wife 6
Age (Years) 66.4 (16.0)
SD, standard deviation.
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Extract 2.
Angela: . . .[H]e says, ‘I think we’ll have a brain scan’ – I says ‘a brain scan?!’ he says ‘it’s
alright, it’s nothing toworry about, it’s just your, youmight be having some trouble with your
memory’ so anyway, I says ‘I don’t want that’. I were thinking of cancer really.
Int: Oh right, I see.
Angela: You do think of cancer first thing. So she said ‘no’, she says ‘we’ll give you’, she says
‘no I don’t think, don’t worry’ – I were worried when I first went up there.
Int: Mm, I’m sure, yeah.
Angela: Anyway, he says ‘well’, he says um ‘we’ll give you a brain scan.’ ‘What? To see
if I’m all there?’ so he says ‘no’ he says anyway, he got me in for a brain scan. Look at
your brain so I says ‘yeah’ and he shows me the diagram he says ‘your brain’s alright –
and believe me you haven’t got cancer’ so I says ‘you sure? That’s what’s been
frightening me, losing it’ so he says ‘no love’ he says ‘no’ he says ‘I think you’ve got a
touch of Alzheimer’s’. (long pause) ‘ooh, what’s that? Have I got to take tablets?’
(woman with MCI, 76 years old)
Many participants continued toworry that MCI could develop into dementia, with this
concern being expressed in 21 interviews. ‘Alison’, who we met in extract 1 when she
spoke about her relief when the diagnosis being downgraded from Alzheimer’s to MCI,
went on to describe how the new diagnostic label failed to assuage her worries, given the
similarities between MCI and dementia: ‘I thought: I haven’t got it, well, what have I got
then? And I were reading that and I thought: what’s this? This is more or less saying a
similar thing to er. . . dementia’. However, others were reassured at the diagnosis, and the
relationship of MCI to dementia and AD was interpreted in heterogeneous ways. One
participant, an 89-year-old retired transport conductor, suggested the clinicians ‘more or
less said that there were no danger from Alzheimer’s for me’. Another – a 60-year-old wife
of a man with MCI – reported never hearing the term at all:
Extract 3.
Int:Ok, ok, erm and atwhat point in this process did you actually hear this termmild cognitive
impairment, when did you?
Lucy:Well I don’t recall ever hearing it, it wasn’t until we got the letter from you.
Int: Interesting, right.
Lucy: So, then [husband] went and saw his doctor, and to ask him and he said don’t worry
about that, don’t worry about that, just carry on, it’s nothing to get worried about, but erm
then [husband] said you know if you feel like being part of that research yes, good for you get
on with it, but that wasn’t, he just wanted to know what this err diagnosis was cos it sort of
came out of the blue.
Int: Right, right, I mean that is a concern from my perspective, if we are erm. . .
Lucy: Maybe if we hadn’t been listening. . .
Int:What words do you remember them saying in the clinic when they, was there any sort of
specific diagnosis?
Lucy:No, noonly that hismemoryhad got less, youknowhehad scored less, andmaybe itwas
like I was quite shocked and maybe I didn’t listen any more, maybe they actually said
something and because Iwas ooo, it had gone downwhen Iwas expecting it to be the same as
or slightly better. . . (wife of man with MCI, 60 years old)
Although we attempted to resolve this issue by clarifying that MCI denotes a stage
of cognitive impairment rather than a definite aetiological diagnosis, and offered to
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re-refer them to the specialist clinic, our findings offer an important cautionary note
for researchers and clinicians working with people with memory impairment. Given
the apparent heterogeneity in clinical communication our participants reported – with
some saying terms like ‘Alzheimer’s’ and ‘dementia’ had been used within the
diagnostic pathway, and others not remembering any clinical terms being used at all –
researchers may be well advised to avoid using the term MCI in participant
information when working with this population, instead using lay terms such as
‘memory loss’. Nevertheless, whatever diagnostic terminology the participants
recalled hearing, worry and uncertainty around prognosis were widespread. This
was expressed by people with MCI and their families, with both groups struggling to
deal with ongoing changes in relationships, and fears that the person with MCI could
become dependent:
Extract 4.
Fiona: The thing that frightens me is that I’m going to have to be. . . ((long pause, sighs))
dependent on someone.
Int: Mm.
Fiona: And I’ll not be able to remember things. That’s the frightening thought. (woman with
MCI, 80 years old)
Extract 5.
Int: Was that the kind of emotion that you associate with all those kind of events you talk
about, so, you know, where you. . .?
Joanne: It scares me, yeah [. . .] because it. . .you just think, wow, because he’s always been
this. . .rock that youwent to and he sorted things out, and as I say, I. . .I always looked after the
kids, I didmy job – I was a teacher, I did the house, I did the food, I did the laundry, but I hadn’t
got a clue who the car was insured with or whether the house was insured or. . .not a clue!
Stupid. . .a really silly situation, but I suddenly thought, you know, I really don’t
know. . .anything! And, again, I’ve sort of, over this time, said to [husband], ‘Perhaps you
could showmehow to that. . .’ andnow, I insure the house, I insure the car, and I am learning a
lot, um, but it’s scary. . . (wife of man with MCI, 75 years old)
Practical benefits and drawbacks of a MCI diagnosis
Understanding what’s wrong
One benefit of diagnosis is being able to name one’s condition and understand likely
prognosis. However, our participants struggled to make sense of the MCI label. They
particularly seemed to find the term ‘cognitive’ problematic. The participants had
clearly not come across the term outside of their engagement with medical and
research professionals:
Extract 6.
Int: I mean what ((tsk)) what does the term mean to you, mild cognitive impairment – if you
had to. . . ((tails off))?
John: Well I had to go and look it up, it didn’t mean anything to me at all. Mild I understand,
impairment I understand, aah. . . I wasn’t sure what was cognitive and what wasn’t. So I did. . .
resort to thedictionary.Um. . . Iwouldn’t say Iwasunduly surprisedby thediagnosis ‘causeum. . .
clearly something’s not right and it’s got to be teased out I suppose. (manwithMCI, 76 years old)
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Extract 7.
Int: So thinking also about that clinic they er. . . they gave you this diagnosis called mild
cognitive impairment.
Susie:What do they call it?
Int: Mild cognitive impairment.
Susie: Connitive impairment?
Int: Cognitive impairment.
Susie: Cognitive?
Int: Um. . . so what does that term mean to you if I were to say ‘mild cognitive impairment’?
Susie: I haven’t a clue. (Woman with MCI, 76 years old)
Sometimes, during the interviews, we were asked what MCI does mean, and we
found ourselves facing an ethical conundrum: On the one hand, we felt an obligation
to our participants to try and explain the meaning of the label, yet we had to
emphasize that, as the interviewing researchers were not clinicians, we were unable
to provide any medical advice. While it would be easy to blame participants’ desire for
clarification on imprecise clinical communication, the above examples suggest that it
may be the MCI label itself which is difficult to interpret. Furthermore, it was not only
the ‘cognitive’ part of the label participants had a problem with – there was a sense
among some that describing their impairments as ‘mild’ failed to grasp the depth of
their difficulties:
Extract 8.
Peter: Shewere tellingme I were grieving and I said ‘no it’s not, it’s memory, it’s not got to do
with grievance’ (pause) and I still think it’s [. . .] I I can’t put it down. . . inmymind the fact that
I’ve got a bad memory has not been caused by grievance.
Int: No, because you’ve said already that. . . this was happening before your wife died.
Peter:Yes, and I couldn’t get through to ‘em [. . .] And I’ve I’ve tried but for some reason I can’t
do it I can’t. . . ((tails off)) seem to, to make ‘em understand that it’s not that. And in that book
that I’m reading [The ChimpParadox by Steve Peters], there it’s, it goes into yourmind. And I
read something in there and I said to [son] ‘this is what I’ve been telling them all the time – it’s
not grievance’. ((pause)) there’s something in there that told me that I’m right and they’re
wrong, but what. . . I forget now what that was. (Man with MCI, 86 years old)
Such accounts were widespread, with almost half our participants questioning the
MCI diagnosis. Often, this arose from a conflict between ‘official’ and ‘unofficial’ truths
(Gomersall, Madill, & Summers, 2012) in which people trusted what they felt at an
embodied, experiential level over the abstract discourse ofmedicine. This certainly seems
to be the case for the participant above, who is sure in his own mind that his cognitive
decline indicates an organic illness, rather than part of grieving. The interviewer and
interviewee perform interactionalwork inwhich both imply his perspective ismore ‘true’
than that of themedical professionals: The participant appeals to the authority of the book
he has been reading as evidence ‘that I’m right and they’re wrong’. The interviewer
provides further detail to support the participant’s assessment (‘this was happening
before your wife died’).
Several participants were similarly unconvinced about the diagnosis, and believed
morewas going on than the doctors had uncovered. One retired clinician we interviewed
was concerned that ‘it [MCI] could be [. . .] fairly defined by various people using it and I
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can understand it might, could lead to misunderstanding of the depth of problems you’re
experiencing’. In one especially poignant example, a participant believed the clinicians
were protecting him from the risk hewould have posed to himself had he been diagnosed
with Alzheimer’s:
Extract 9
Brian: . . .[T]he first thing he said tomewas ‘it is definitelynotAlzheimer’s’. . . and I thought –
why has he said that? Why did he say that? Is he, are they trying to block it out for what I said?
((long pause)) you know what I told the doctor, don’t you?
Int: No I’m not sure.
Brian:Rightwellwhat I did saywas I said ‘if you tellme I’ve got Alzheimer’s. . . I’mnot long for
this world’ I said ‘because I can’t cope with that’.
Int: Mm-hmm.
Brian:Um. . . and I upset her, I upset the girl shewere, I were so sorry that I’d said it but she’d
asked me and er. . . and I thought – I wonder if he’s telling me this and I have got it? Are they
tellingme [it’s MCI] because they don’t wantme to do. . . ((tails off)). (ManwithMCI, 60 years
old)
Conversely, some participants believed that MCI inappropriately appends a
diagnostic label to the ageing process. These participants engaged in a kind of lay
critique of diagnostic creep, suggesting there was little sense in treating memory
impairment at their stage of life as an ‘illness’. One 84-year-old woman recounted how
her friend ‘roared with laughter’ upon learning she would be attending the memory
clinic. However, while some participants critiqued the reliability or usefulness of the
MCI label, others accepted the diagnosis with deference to clinical judgement. One
woman explained that she preferred not to know too much about her cognitive
impairment. She wished to live her life without dwelling on her memory problems,
trusting the experts to manage any clinical issues:
Extract 10.
INT:Okay. Sowhat did they tell you about the scan?Did they sort of give you some results from
that or. . .?
Veronica: No, no, no.
INT: So you didn’t hear back. . .
Veronica:The thingwithme, I tend to just do as they say and that’s it, you knowwhat Imean. I
don’t really ask a lot of questions but I think the less you know, the better it is ((laughing)), you
know what I mean? I know it sounds a bit silly that but. . .
INT: No, no, I mean, that. . .
Veronica: I don’t want to know. Just get onwith it, yeah! [. . .] You’re in the best hands, aren’t
you? I mean, you can sit at home and feel sorry for yourself, but if you don’t do nowt about it,
that’s it, so you’ve got to dowhat. . .you’ve got tomake the best of what you can, haven’t you?
(woman with MCI, 81 years old)
Practical benefits and drawbacks: Medical management
Seeking medical advice can, potentially, offer a range of practical benefits. Naming a
condition can change a set of signs and symptoms into a ‘known’ condition,
potentially opening options for clinical management and the relief of suffering.
However, in the UK, no specific treatments are currently recommended for the
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medical management of MCI, and this was a source of frustration to several
participants, with many desiring medical management to arrest further decline. One
participant, upon arriving at the interview, asked if we could provide antidementia
drugs. Almost half of our participants spontaneously stated that what they most
desired from the memory clinic was a cure (e.g., Extract 11), and one daughter of a
man with MCI even reported seeking memory-enhancing drugs for herself (Extract
12):
Extract 11.
Fiona: It would be lovely to come up with a medicine that just kept your head working
properly, I don’t think there’ll ever manage to do that somehow. Not unless there’s
some vitamins or something you know that help but it would be lovely if you could
think there was and to me that even if they didn’t do that much good it could do good
to yourself sort of thing, you’d feel more that you could do things. (woman with MCI,
80 years old)
Extract 12.
Amy: I’ll definitely end up with what me Dad’s got, hundred million percent because my
memory is atrocious! It is er, cannot remember things, it’s driving me mad and one of girls,
(name) is same and she keeps buying all these medications which are coming out on market
now to supposedly boost your memory. (Daughter of man with MCI, 47 years old)
Although the desire for medication was voiced by multiple participants, others were
hesitant about over-medicating. In some cases, the key advantage of seeking medical
advicewas not to find away tomedically ‘treat’ theirmemory loss –what theywantedwas
a sense that support was there, and could be called upon, if and when it was needed – as
we see in Extract 13:
Extract 13.
Int: So they’re following you up?
David: Yeah, and I, I appreciate it.
Int: Right.
David: I know if there’s something radically wrong with me, then they’ll let me know, and if
there’s anything that could be done, it’ll be done.
Int: So it sounds like you’re kind of. . . reassured by the memory service?
David:Yes it, it is a reassurance that if there is anythingwrongwithme they’ll at least try toput
it right – and if they can’t ((laughs)) oh well! That’s it. (Man with MCI, 89 years old)
Clinical services, then, were important to our participants not simply in terms of
dispensing appropriate treatments, but as a reassuring source of support they knew they
could drawonwhen needed. In the interim,without any specificmedicines to slow down
or prevent cognitive decline available for prescription, our participants reported a range
of informal self-management strategies tomaintain cognition – crosswords, puzzles, ‘brain
training’ games, and diary keeping. In linewith previous research inMCI andAD, andwith
the move towards treating patients as experts on their illnesses, our participants took the
lead on managing the changes they experienced, with clinical services playing a
supporting role in the background of their lives.
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Discussion
Mild cognitive impairment describes a decline in cognition between ‘normal’ cognitive
ageing and dementia. Given the persistent problemswith early detection and treatment of
dementia (Vernooij-Dassen et al., 2005), MCI may be a helpful label to manage cases of
uncertain dementia status. Although MCI is a useful category from clinical and research
perspectives, few of our participants identified with the label, and found it had limited
explanatory power for clarifying their problems. In common with previous research, we
also found that MCI could cause some interactional difficulties for participants – for
instance, in terms of ‘courtesy stigma’ (Beard & Neary, 2013), or in difficulties to
explaining their diagnosis to friends and family. However, in contrast to thework of Beard
(2016) on reactions to receiving an MCI/early AD diagnosis, few of our participants
appeared to have embarked on an ‘illness career’. Some of the impairments reported by
participants posed a threat to their identities and independence, but the general pattern
was one of attempting to exercise their cognitive abilities and make small adaptations to
enable continued participation in valued activities. Additionally, none of our participants
had joined AD support groups. The emphasis was on trying to continue living ‘normally’.
Diagnostic labels can be thought of as ‘master signifiers’ – they takemultiple sources of
complex information, and reduce them to a labelwhich explains thewhole. As Verhaeghe
(2008) puts it, ‘a name always carries with it [. . .] the illusion of control and mastery.
Nothing is worse than not being able to name something; once a name has been found, it
seems manageable’ (p. 61). This, perhaps, is one reason why so many people describe
feelings of relief when they receive a serious diagnosis – it can make legible what had
previously been impenetrable, threatening, unknowable. In some cases, this phe-
nomenon of relief at receiving a serious diagnosis has even been noted in studies of
dementia (Robinson et al., 2011). In our interviews, although participants were relived
not to have been diagnosed with dementia, their relief was tempered by continued
uncertainty.
Our participants appeared to interpret MCI inmany and variedways. On the one hand,
some participants were unfamiliar with the technical term ‘cognitive’; yet the banality of
the terms ‘mild’ and ‘impairment’ may also have compounded difficulties in understand-
ing. This certainly points to the significance of work in behavioural economics showing a
gulf between lay and expert understandings of technical language (Bruine de Bruin &
Bostrom, 2013; Fischhof, 1995). However, it is not simply that clinical experts have amore
sophisticated understanding of the ‘real’ nature of MCI – as our data showed, our
participants offered sophisticated criticisms of MCI as a clinical entity. For instance, the
idea that the symptoms ofMCImaybepart of the ageing processwasmentionedby several
participants. Others suggested theymay have a better grasp of the extent of their memory
problems than standardized clinical testing could offer, as they lived with the impairment
day-to-day. Finding a way to bridge the gap between lay and expert perspectives, for
instance using a structured way to explain the meaning of cognition in clinical
consultations, may aid communication. Although some researchers have examined the
various ways clinicians communicate with people with MCI (e.g., Saunders et al., 2011),
as yet no research exists on developing and testingways to communicate anMCI diagnosis
in terms of patient satisfaction and understanding.
The potential for MCI to progress to dementia was a source of further uncertainty for
our participants. Despite an increasing number of prognosticMCI studies (e.g., Rosenberg
et al., 2013), it is not possible in routine clinical practice to predict who will go on to
develop more serious neurocognitive conditions, or indeed who will revert to previous
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levels of functioning (Sachdev et al., 2013). Although clinicians can offer general
information on risk of progressing to dementia among the population of people with
MCI, risk communication is a highly complex and ethically fraught business. Several
different conceptions of risk, underpinned by very different ontological and statistical
assumptions, are routinely used in patient counselling (O’Doherty, 2006). It was evident
from Our interviews that people were interpreting risk in a variety of ways. Some were
convinced they had dementia anyway, or were inevitably heading in that direction,
while others read the information as meaning that MCI was part and parcel of ageing.
Most, however, fell between these extremes, with some awareness of the risk of
progressing to dementia. It may be that those who live with cognitive impairments are
personally aware of problems that are not picked up by standardized testing, as a number
of our participants suggested – and indeed, self-reported memory complaints have
demonstrated some prognostic value in previous studies (Mitchell & Shiri-Feshki, 2009).
Another finding was the desire among several participants for medical management.
While MCI may be treated with Cholinesterase inhibitors in the United States, no
pharmacological treatments are recommended for MCI in the United Kingdom – and the
greater part of research efforts have been devoted to behavioural and other non-
pharmacological approaches to management. What clinical services can do to support
people with MCI to live well and maintain cognitive function, both medically and
occupationally, is an important question to address in coming years as increasing numbers
of people present to clinical services with potential prodromal dementia.
Aswith any qualitative research, the generalizability of our findings is limited.Wewere
unable to purposively recruit participants, and consequently, our sample was relatively
homogeneous in terms of age, ethnicity, and geographical location. This latter point is
especially important – there are likely to be wide variations nationally in how MCI is
diagnosed in clinical practice, and so our data only provide a snapshot of one clinic in the
North of England. However, our work is not the first piece of research to have identified
problems in understanding MCI (Beard & Neary, 2013; Blieszner, Roberto, Wilcox,
Barham, & Winston, 2007; Lingler et al., 2006), and so our findings lend support to the
possibility that this is a persistent issue.
In conclusion, MCI is a difficult category to understand from a lay perspective. The
complex relationship between MCI, serious neurocognitive disorders, and ‘normal’
ageing is a source of uncertainty and confusion among people living with the diagnosis,
and the lack of recommended medical treatments can be a source of frustration. Work is
needed to understand how MCI is discussed in clinical consultations, and what can be
done to support people in managing their cognitive difficulties.
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Appendix 1: Semi-structured topic guides
Topic guide
Introduction: Reiterate the purpose of the interview, and the form it will take. Emphasize
role as learner, and interest in the participant’s own ‘insider’ knowledge, experiences, and
stories.
Topic 1. Changes in the person and relationships
Can you tell me about the time you first noticed a change in yourself?
 (if not covered above) – clarify domain(s) of impairment
 Follow-up to gain asmanyparticular incident narratives as possible:What happened
then?
How do you find your (memory/attention/speech – use pt’s word) at the moment?
 As many examples as possible
 Pick up on things pt mentions and push for particular narratives – ‘what happened
at that time?’
Sometimes, when people are diagnosedwith problems in (attention/memory/use pt’s
word), they can change in other ways, too. Have you noticed any other changes recently?
 As many examples as possible.
 Push for particular narratives – ‘what happened at that time?’
Can you think of any ways your relationships have changed recently?
Topic 2. Hobbies and activities
One thing we would like to find out about is whether living with someone with (use pt’s
word) affects the things people enjoy doing on a day-to-day basis. So, please can you tell
me about the things you enjoy doing?
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 If needed, clarify this could be anything they like: professional activities, hobbies,
household work, seeing family and friends, etc.
 Push for particular narratives – ‘can you tell me about any times you’ve done X?’
 As many examples as possible.
Do you have any ideas about what might help you keep up with (activity) in future
years?
Topic 3. Experience of diagnosis
Was there anything in particular that made you decide to go to the doctor about (use pt’s
word)?
 Push for as many particular narratives as possible
Thinking about your first visit to the memory clinic, can you tell me a bit about what
happened on that day?
 Explore thoughts/feelings during the visit with the participant. Issues to cover if pt
does not mention them: experience of referral; experience of assessment process;
what the doctor told them was the diagnosis (and how they said it).
Interview close
Summarize the interview: reiterate all key issues/stories. Clarify that you have understood
him/her in the way they wish. Ask participant: Is there anything we’ve not covered, or
anything else you’d like to tell me?
Partners’ topic guide
Introduction: Reiterate the purpose of the interview, and the form it will take. Emphasize
role as learner, and interest in theparticipant’s own ‘insider’ knowledge, experiences, and
stories.
Topic 1. Changes in the person and relationship
Can you tell me about the time you first noticed a change in (partner)?
 (if not covered above) – clarify domain(s) of impairment
 Follow-up to gain asmany particular incident narratives as possible:What happened
then?
How do you find (partner)’s (memory/attention/speech – use pt’s word) at the
moment?
 As many examples as possible
 Push for particular narratives – ‘what happened at that time?’
Sometimes, when people are diagnosed with problems in (attention/memory/use pt’s
word), they can change in other ways, too. Have you noticed any other changes in
(partner) recently?
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 As many examples as possible.
 Push for particular narratives – ‘what happened at that time?’
Can you think of any ways your relationship with (partner) has changed recently?
Topic 2. Hobbies and activities
One thing we would like to find out about is whether living with someone with (use pt’s
word) affects the things people enjoy doing on a day-to-day basis. So, please can you tell
me about the things you enjoy doing?
 If needed, clarify this could be anything they like: professional activities, hobbies,
household work, seeing family and friends, etc.
 Push for particular narratives – ‘can you tell me about any times you’ve done X?’
(If not explored after above question): Have (partner)’s problems affected (activities x,
y, z) in any way?
 As many examples as possible.
Do you have any ideas about what might help you keep up with (activity) in future
years?
Topic 3. Experience of diagnosis
Was there anything in particular that made you decide to go to the doctor about (use pt’s
word)?
 Push for as many particular narratives as possible
Thinking about your first visit to the memory clinic, can you tell me a bit about what
happened on that day?
 Explore thoughts/feelings during the visit with the participant. Issues to cover if pt
does not mention them: experience of referral; experience of assessment process;
what the doctor told them was the diagnosis (and how they said it).
Interview close
Summarize the interview: reiterate all key issues/stories. Clarify that you have understood
him/her in the way they wish. Ask participant: Is there anything we’ve not covered, or
anything else you’d like to tell me?
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